Perceptive Life Sciences, a fund that has outperformed the market, sold all of its 1 million shares of Novavax in the first few months of… Read More »An Outperforming Fund Ditched Novavax And Picked Up These 3 Biotech Stocks
The small-cap biopharmaceutical stock featured in today’s article is a Buy according to the consensus among analysts, who see upside potential of nearly 200% from… Read More »Analysts Say This Small-Cap Biopharmaceutical Stock Is A Buy
The company featured in today’s article finds itself at the intersection of biotech and cannabis – an intersection that could be worth $50 billion by… Read More »A Lucrative Opportunity At The $50 Billion Intersection Of Biotech And Cannabis
New Biotech World Order – surging share prices and booming initial public offerings of biotech stocks.
The two biotechs that are the focus of today’s article have been hot this year, with shares of both having experienced triple-digit growth. The reason?… Read More »The Case Against These Two Hot COVID-19 Vaccine Stocks